Mer receptor expression promotes multiple myeloma disease development via a cell-extrinsic mechanism

Résumé fourni par la source

Multiple myeloma (MM) is an incurable haematological malignancy characterised by the uncontrolled proliferation of bone marrow resident plasma cells (PCs). Two members of the TAM (TYRO3, AXL and MER) receptor family have previously been implicated in distinct aspects of neoplastic PC biology. AXL expression in MM PCs has been associated with induction of a dormant, non-cycling state within the bone marrow, whereas expression of MER has been implicated in PC proliferation and survival. Here, generation of single TAM receptor expressing 5TGM1 murine MM cell lines enabled the individual functional assessment of the effects of Axl and Mer receptor expression on MM development. Axl expression did not affect proliferation, cell cycling, or stromal cell induced dormancy in vitro . Development of 5TGM1 tumours in C57BL/KaLwRij mice was also unaltered by Axl expression. By contrast, Mer expression conferred an increase in cell proliferation to 5TGM1 cells in vitro, and increased 5TGM1 tumour burden in C57BL/KaLwRij mice. The pro-tumourigenic properties of Mer were only observed following intravenous cell delivery into mice with an intact adaptive immune system. Thus, Axl is neither necessary nor sufficient for induction of MM cancer cell dormancy, whereas Mer remains a promising target for therapeutic intervention in MM patients. Teaser abstract: Multiple myeloma (MM) is an incurable haematological malignancy of plasma cells (PCs). Two members of the TAM (TYRO3, AXL and MER) receptor family have previously been implicated in distinct aspects of MM PC biology. AXL expression in MM PCs has been associated with induction of dormancy, whereas expression of MER has been implicated in PC proliferation and survival. Using mouse myeloma cell lines expressing single TAM receptors, we demonstrate that Axl is neither necessary nor sufficient for induction of MM cancer cell dormancy, whereas Mer promotes tumour development and remains a promising therapeutic target in MM patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.